Evidence map›Paper›PMID 34054532›Full record

ReviewFrontiers in pharmacology2021

Multi-Omics Approach in the Identification of Potential Therapeutic Biomolecule for COVID-19.

Rachana Singh, Pradhyumna Kumar Singh, Rajnish Kumar, Md Tanvir Kabir, Mohammad Amjad Kamal, Abdur Rauf, Ghadeer M Albadrani, Amany A Sayed, Shaker A Mousa, Mohamed M Abdel-Daim and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Plant asparaginase versus microbial asparaginase as anticancer agent.Environmental science and pollution research international · 2022
    Article
  8. Exploring the therapeutic potential of marine-derived bioactive compounds against COVID-19.Environmental science and pollution research international · 2021
    Review
  9. Kidney injury in COVID-19 patients, drug development and their renal complications: Review study.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rachana SinghAmity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow, India.
Pradhyumna Kumar SinghPlant Molecular Biology and Biotechnology Division, Council of Scientific and Industrial Research- National Botanical Research Institute (CSIR-NBRI), Lucknow, India.
Rajnish KumarAmity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow, India.
Md Tanvir KabirDepartment of Pharmacy, Brac University, Dhaka, Bangladesh.
Mohammad Amjad KamalWest China School of Nursing/Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Abdur RaufDepartment of Chemistry, University of Swabi, Khyber Pakhtunkhwa, Pakistan.
Ghadeer M AlbadraniDepartment of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Amany A SayedZoology Department, Faculty of Science, Cairo University, Giza, Egypt.
Shaker A MousaPharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, United States.
Mohamed M Abdel-DaimPharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt.
Md Sahab UddinDepartment of Pharmacy, Southeast University, Dhaka, Bangladesh.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has a disastrous effect on mankind due to the contagious and rapid nature of its spread. Although vaccines for SARS-CoV-2 have been successfully developed, the proven, effective, and specific therapeutic molecules are yet to be identified for the treatment. The repurposing of existing drugs and recognition of new medicines are continuously in progress. Efforts are being made to single out plant-based novel therapeutic compounds. As a result, some of these biomolecules are in their testing phase. During these efforts, the whole-genome sequencing of SARS-CoV-2 has given the direction to explore the omics systems and approaches to overcome this unprecedented health challenge globally. Genome, proteome, and metagenome sequence analyses have helped identify virus nature, thereby assisting in understanding the molecular mechanism, structural understanding, and disease propagation. The multi-omics approaches offer various tools and strategies for identifying potential therapeutic biomolecules for COVID-19 and exploring the plants producing biomolecules that can be used as biopharmaceutical products. This review explores the available multi-omics approaches and their scope to investigate the therapeutic promises of plant-based biomolecules in treating SARS-CoV-2 infection.

Indexed as

biomoleculescoronavirusCOVID-19multi-omicsSARS-CoV-2therapeutic molecules

Identifiers

PMID34054532
PMCPMC8149611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.